Antifungal

PNU Researchers Reveal Cutibacterium acnes as a Potential Cause of Lichen Striatus Hypopigmentation

Retrieved on: 
Wednesday, January 17, 2024
Patient, Research, Associate, Professor, Skin, Whole genome sequencing, Acne, Comamonas, Pusan National University, Quality of life, Bacteria, Blaschko's lines, Journal, Observation, Microbiota, Health informatics, Biopsy, Hypopigmentation, Antifungal, Sulfur

The gram-positive bacterium Cutibacterium acnes has previously been associated with various skin conditions, including acne vulgaris and post-inflammatory hypopigmentation.

Key Points: 
  • The gram-positive bacterium Cutibacterium acnes has previously been associated with various skin conditions, including acne vulgaris and post-inflammatory hypopigmentation.
  • There could, therefore, be a potential association between C. acnes and the observed skin microbiota of patients with LS with and without hypopigmentation.
  • Comparing patients with LS with and without hypopigmentation, the researchers discovered a quadrupled presence (23.26% versus 5.29% of the entire microbiota) of Cutibacterium acnes in the former.
  • Title of original paper: Association between the skin microbiome and lichen striatus hypopigmentation: Cutibacterium acnes as a potential cause

Basilea provides portfolio status update

Retrieved on: 
Friday, January 5, 2024
European Commission, Partnership, Yeast, ABSSSI, Fungus, FDA, Antifungal, PDUFA, DXR, WHO, European, Staphylococcus aureus, Genetically modified bacteria, NDA, Bronchopneumonia, SAB, Civil service commission, USD, Infection, Candida auris, Fungal infection, World Health Organization, Biofilm, Patient, Staphylococcus, CABP, Pharmaceutical industry

By year-end 2023, Cresemba was marketed in more than 70 countries, including the United States (US), most EU member states, China and Japan.

Key Points: 
  • By year-end 2023, Cresemba was marketed in more than 70 countries, including the United States (US), most EU member states, China and Japan.
  • In August, Basilea submitted a similar application for a pediatric label extension of Cresemba in the European Union and anticipates a decision by the European Commission around mid-2024.
  • Basilea expects to enter into a commercialization partnership agreement for ceftobiprole in the US prior to the FDA decision.
  • For fosmanogepix, Basilea anticipates to start a phase 3 study in invasive yeast infections mid-2024 and a phase 3 study in invasive mold infections, by year-end 2024.

Matinas BioPharma Reports Third Quarter 2023 Financial Results and Provides a Business Update

Retrieved on: 
Wednesday, November 8, 2023
FDA, Antifungal, NYSE, Food, Conference, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, LNC, Partnership, Infection, Conference call, Fungal infection, Patient, Pharmaceutical industry, Medical imaging

BEDMINSTER, N.J., Nov. 08, 2023 (GLOBE NEWSWIRE) -- Matinas BioPharma (NYSE American: MTNB), a clinical-stage biopharmaceutical company focused on delivering groundbreaking therapies using its lipid nanocrystal (LNC) platform delivery technology, reports financial results for the three and nine months ended September 30, 2023 and provides a business update.

Key Points: 
  • “We are very excited by the consistent, positive clinical data generated with MAT2203 in our Compassionate/Expanded Use Access Program.
  • We’re highly encouraged by FDA’s openness to a superiority composite primary endpoint, which could be significant in positioning MAT2203 for commercial success.
  • The revised superiority composite endpoint is being finalized and will be submitted to FDA for alignment in the next few weeks.
  • Total costs and expenses for the third quarter of 2023 were $6.1 million compared with $6.5 million for the third quarter of 2022.

F2G and Shionogi Present Full Data Set from Pivotal Phase 2b Study at Trends in Medical Mycology (TIMM) 2023 Demonstrating Positive Therapeutic Responses in Patients with Invasive Fungal Infections Treated with Oral Olorofim

Retrieved on: 
Saturday, October 21, 2023
Standard of care, TIMM, Immunodeficiency, Congress, MD, EORTC, Doctor of Philosophy, Fungus, Research, Coccidioidomycosis, DRC, Shionogi, UZ Leuven, Hematology, OASIS, Scopulariopsis, World Health Organization, Risk, Antifungal, Medical Mycology, ACM, Fungal infection, Goodyear F2G Corsair, Patient, Infection, Birth control, Pharmaceutical industry, Coccidioides, F2G

These findings were submitted as a late breaking abstract and exceptionally accepted for an oral presentation during the 11th Congress on Trends in Medical Mycology (TIMM) 2023 held in Athens, Greece, from 20-23 October 2023.

Key Points: 
  • These findings were submitted as a late breaking abstract and exceptionally accepted for an oral presentation during the 11th Congress on Trends in Medical Mycology (TIMM) 2023 held in Athens, Greece, from 20-23 October 2023.
  • F2G and Shionogi & Co., Ltd. are collaborating to develop and commercialise olorofim, bringing the novel antifungal therapy to patients with invasive fungal infections.
  • F2G has commercial responsibility for olorofim in North America, and Shionogi has commercial responsibility for olorofim in Europe and Asia Pacific.
  • F2G and Shionogi are currently enrolling patients with invasive aspergillosis in a global Phase 3 study (OASIS) to compare treatment with olorofim versus AmBisome® followed by standard of care ( NCT05101187 ).

Pulmocide Announces New Clinical Data Confirming Low Potential for Drug-Drug Interactions with Inhaled Opelconazole

Retrieved on: 
Monday, October 16, 2023
ID, Cytochrome P450, Midazolam, Chronic pulmonary aspergillosis, Antifungal, Risk, Inhalation, Disease, Drug, Clinical trial, Bronchospasm, Caffeine, CYP1A2, Patient, CYP3A4, Pharmaceutical industry

The results from these in vitro studies subsequently informed the design of a Phase 1 drug-drug interaction study in 24 healthy volunteers.

Key Points: 
  • The results from these in vitro studies subsequently informed the design of a Phase 1 drug-drug interaction study in 24 healthy volunteers.
  • “Opelconazole was specifically designed to be administered via inhalation in order to achieve high lung concentrations and low systemic uptake.
  • These low systemic levels, now observed in multiple clinical trials and in the UK Special Needs provision, have been estimated to be too low to have an inhibition or induction of a drug-drug interaction effect.
  • We are encouraged that these clinical trial results confirm this low potential for Cytochrome P450 drug-drug interactions for opelconazole.”

CorMedix Inc. Announces Abstract Presentation at Upcoming IDWeek Conference

Retrieved on: 
Wednesday, October 11, 2023
Antifungal, Fluconazole, Bloodstream infections, Candida auris, Taurolidine, Pharmaceutical industry

The abstract being presented highlights data regarding in vitro activity of taurolidine against the fungus Candida auris, an emerging cause of life-threatening bloodstream infections, with increasing resistance to common antifungal agents.

Key Points: 
  • The abstract being presented highlights data regarding in vitro activity of taurolidine against the fungus Candida auris, an emerging cause of life-threatening bloodstream infections, with increasing resistance to common antifungal agents.
  • Taurolidine exhibited in vitro antimicrobial activity against all C. auris strains and isolates regardless of geographic source, year of isolation, or clade.
  • There was no evidence that taurolidine activity was affected by resistance to amphotericin B or fluconazole.
  • The abstract is available through the IDWeek conference website.

Matinas BioPharma Reports Second Quarter 2023 Financial Results and Provides a Business Update

Retrieved on: 
Wednesday, August 9, 2023
BioNTech, CT, Nephrotoxicity, IV, Diabetes, Hospital, Mucor, Conference call, Clinical trial, Women's Hospital International and Fertility Centre, Infection, Brain, LNC, Research, Biomedical Research, European Congress of Ethnic Religions, Messenger, Lung, Acute myeloid leukemia, Development, MRI, Kidney, National Resilience Institute, ECCMID, MD, Patient, Standard of care, Azole, Microsoft Access, RNA interference, Fungal infection, FDA, Nationwide, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, BARDA, Conference, NYSE, Food, Female, Pharmaceutical industry, Medical imaging, Antifungal

BEDMINSTER, N.J., Aug. 09, 2023 (GLOBE NEWSWIRE) --  Matinas BioPharma (NYSE American: MTNB), a clinical-stage biopharmaceutical company focused on delivering groundbreaking therapies using its lipid nanocrystal (LNC) platform delivery technology, reports financial results for the three and six months ended June 30, 2023 and provides a business update.

Key Points: 
  • Matinas’ collaboration with National Resilience continues to focus on in vitro and in vivo delivery of mRNA and expects initial data later in 2023.
  • The Company reported no revenue for the second quarter of 2023 compared with $1.1 million of revenue for the second quarter of 2022, which was generated from the Company’s research collaborations with BioNTech SE.
  • Total costs and expenses for the second quarter of 2023 were $6.2 million compared with $7.0 million for the second quarter of 2022.
  • The net loss for the second quarter of 2023 was $6.1 million, or $0.03 per share, compared with a net loss for the second quarter of 2022 of $5.9 million, or $0.03 per share.

Nanorobotics System Presents New Options for Targeting Fungal Infections

Retrieved on: 
Monday, July 31, 2023
Infection, Oxygen, Candida albicans, Antifungal, Innovation, Global health, Fungus, Drug resistance, ROS, Motion, Reactive oxygen species, Water, University of Pennsylvania School of Engineering and Applied Science, World Health Organization, Field line, Antibiotics, Environmental remediation, Vaccine, Advanced Materials

They achieved this by using electromagnetic fields to control the shape and movements of these nanozyme microrobots with great precision.

Key Points: 
  • They achieved this by using electromagnetic fields to control the shape and movements of these nanozyme microrobots with great precision.
  • However, the pioneering element of these nanozyme assemblies was their strong binding affinity to fungal cells.
  • Its precise targeting, rapid action suggest potential for treating other types of stubborn infections.
  • "We've uncovered a powerful tool in the fight against pathogenic fungal infections," Koo says.

Endo Launches First Generic Version of Noxafil® (posaconazole) Injection

Retrieved on: 
Thursday, June 29, 2023
CLL, Hypersensitivity, Lymphocytosis, Pimozide, Arrhythmia, Tacrolimus, Chronic lymphocytic leukemia, SLL, Liver disease, Simvastatin, Magnesium, Atorvastatin, Antifungal, Person, QT, Sirolimus, QT interval, Ergot, Alkaline phosphatase, Plasma, Kidney, Lovastatin, Ergotism, Patient, Azole, Risk, Electrolyte, Ergotamine, Dihydroergotamine, Tumor lysis syndrome, Ciclosporin, ALT, Quinidine, Rhabdomyolysis, Potassium, AST, Venetoclax, Pharmaceutical industry, Posaconazole, CYP3A4

Concomitant administration of posaconazole with sirolimus increases the sirolimus blood concentrations by approximately 9-fold and can result in sirolimus toxicity.

Key Points: 
  • Concomitant administration of posaconazole with sirolimus increases the sirolimus blood concentrations by approximately 9-fold and can result in sirolimus toxicity.
  • Posaconazole may increase the plasma concentrations of ergot alkaloids (ergotamine and dihydroergotamine) which may lead to ergotism.
  • Reserve azole antifungals, including posaconazole injection, for patients receiving a vinca alkaloid, including vincristine, who have no alternative antifungal treatment options.
  • Posaconazole injection is indicated for the treatment of invasive aspergillosis in adults and pediatric patients 13 years of age and older.

Endo Launches First Generic Version of Noxafil® (posaconazole) Injection

Retrieved on: 
Thursday, June 29, 2023
CLL, Hypersensitivity, Lymphocytosis, Pimozide, Arrhythmia, Tacrolimus, Chronic lymphocytic leukemia, SLL, Liver disease, Simvastatin, Magnesium, Atorvastatin, Antifungal, Person, QT, Sirolimus, QT interval, Ergot, Alkaline phosphatase, Plasma, Kidney, Lovastatin, Ergotism, Patient, Azole, Risk, Electrolyte, Ergotamine, Dihydroergotamine, Tumor lysis syndrome, Ciclosporin, ALT, Quinidine, Rhabdomyolysis, Potassium, AST, Venetoclax, Pharmaceutical industry, Posaconazole, CYP3A4

Concomitant administration of posaconazole with sirolimus increases the sirolimus blood concentrations by approximately 9-fold and can result in sirolimus toxicity.

Key Points: 
  • Concomitant administration of posaconazole with sirolimus increases the sirolimus blood concentrations by approximately 9-fold and can result in sirolimus toxicity.
  • Posaconazole may increase the plasma concentrations of ergot alkaloids (ergotamine and dihydroergotamine) which may lead to ergotism.
  • Reserve azole antifungals, including posaconazole injection, for patients receiving a vinca alkaloid, including vincristine, who have no alternative antifungal treatment options.
  • Posaconazole injection is indicated for the treatment of invasive aspergillosis in adults and pediatric patients 13 years of age and older.